## Allison Carol Nugent

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8411240/publications.pdf

Version: 2024-02-01

87 papers

8,503 citations

42 h-index 84 g-index

89 all docs 89 docs citations

times ranked

89

11864 citing authors

#	Article	IF	CITATIONS
1	Common genetic variants influence human subcortical brain structures. Nature, 2015, 520, 224-229.	27.8	772
2	The ENIGMA Consortium: large-scale collaborative analyses of neuroimaging and genetic data. Brain Imaging and Behavior, 2014, 8, 153-182.	2.1	696
3	Identification of common variants associated with human hippocampal and intracranial volumes. Nature Genetics, 2012, 44, 552-561.	21.4	594
4	Reduced Serotonin Type 1A Receptor Binding in Panic Disorder. Journal of Neuroscience, 2004, 24, 589-591.	3.6	350
5	Glutamate and Gamma-Aminobutyric Acid Systems in the Pathophysiology of Major Depression and Antidepressant Response to Ketamine. Biological Psychiatry, 2017, 81, 886-897.	1.3	334
6	Reduced hippocampal volume in unmedicated, remitted patients with major depression versus control subjects. Biological Psychiatry, 2005, 57, 935-937.	1.3	250
7	Novel genetic loci associated with hippocampal volume. Nature Communications, 2017, 8, 13624.	12.8	250
8	Neural and Behavioral Responses to Tryptophan Depletion in UnmedicatedPatients With Remitted Major Depressive Disorder and Controls. Archives of General Psychiatry, 2004, 61, 765.	12.3	245
9	Grey matter differences in bipolar disorder: a metaâ€analysis of voxelâ€based morphometry studies. Bipolar Disorders, 2012, 14, 135-145.	1.9	243
10	Frontotemporal Alterations in Pediatric Bipolar Disorder. Archives of General Psychiatry, 2005, 62, 734.	12.3	240
11	Novel genetic loci underlying human intracranial volume identified through genome-wide association. Nature Neuroscience, 2016, 19, 1569-1582.	14.8	213
12	Cortical abnormalities in bipolar disorder investigated with MRI and voxel-based morphometry. Neurolmage, 2006, 30, 485-497.	4.2	191
13	Ketamine has distinct electrophysiological and behavioral effects in depressed and healthy subjects. Molecular Psychiatry, 2019, 24, 1040-1052.	7.9	187
14	Selective reduction in amygdala volume in pediatric anxiety disorders: A voxel-based morphometry investigation. Biological Psychiatry, 2005, 57, 961-966.	1.3	183
15	Serotonin Transporter Binding in Bipolar Disorder Assessed using [11C]DASB and Positron Emission Tomography. Biological Psychiatry, 2006, 60, 207-217.	1.3	183
16	Neural correlates of change in major depressive disorder anhedonia following open-label ketamine. Journal of Psychopharmacology, 2015, 29, 596-607.	4.0	175
17	Prefrontal cortical abnormalities in currently depressed versus currently remitted patients with major depressive disorder. Neurolmage, 2011, 54, 2643-2651.	4.2	170
18	Ketamine and other N-methyl-D-aspartate receptor antagonists in the treatment of depression: a perspective review. Therapeutic Advances in Chronic Disease, 2015, 6, 97-114.	2.5	169

#	Article	IF	CITATIONS
19	Habenula Volume in Bipolar Disorder and Major Depressive Disorder: A High-Resolution Magnetic Resonance Imaging Study. Biological Psychiatry, 2011, 69, 336-343.	1.3	159
20	Differential Effects of 5-HTTLPR Genotypes on the Behavioral and Neural Responses to Tryptophan Depletion in Patients With Major Depression and Controls. Archives of General Psychiatry, 2006, 63, 978.	12.3	140
21	Neural Correlates of Rapid Antidepressant Response to Ketamine in Treatment-Resistant Unipolar Depression: A Preliminary Positron Emission Tomography Study. Biological Psychiatry, 2013, 73, 1213-1221.	1.3	139
22	Default Mode Connectivity in Major Depressive Disorder Measured Up to 10 Days After Ketamine Administration. Biological Psychiatry, 2018, 84, 582-590.	1.3	123
23	Reduced Posterior Hippocampal Volume in Posttraumatic Stress Disorder. Journal of Clinical Psychiatry, 2008, 69, 1087-1091.	2.2	121
24	The Effects of Tryptophan Depletion on Neural Responses to Emotional Words in Remitted Depression. Biological Psychiatry, 2009, 66, 441-450.	1.3	108
25	Reduced Muscarinic Type 2 Receptor Binding in Subjects With Bipolar Disorder. Archives of General Psychiatry, 2006, 63, 741.	12.3	106
26	The Relationship between Glucose Metabolism, Resting-State fMRI BOLD Signal, and GABA <sub>A</sub> -Binding Potential: A Preliminary Study in Healthy Subjects and Those with Temporal Lobe Epilepsy. Journal of Cerebral Blood Flow and Metabolism, 2015, 35, 583-591.	4.3	104
27	Altered Cerebral γ-Aminobutyric Acid Type A–Benzodiazepine Receptor Binding in Panic Disorder Determined by [11C]Flumazenil Positron Emission Tomography. Archives of General Psychiatry, 2008, 65, 1166.	12.3	103
28	Amygdala volume in depressed patients with bipolar disorder assessed using high resolution 3T MRI: The impact of medication. Neurolmage, 2010, 49, 2966-2976.	4.2	103
29	Group differences in MEG-ICA derived resting state networks: Application to major depressive disorder. Neurolmage, 2015, 118, 1-12.	4.2	103
30	Automated subcortical segmentation using FIRST: Test-retest reliability, interscanner reliability, and comparison to manual segmentation. Human Brain Mapping, 2013, 34, 2313-2329.	3.6	98
31	Lateralization and gender differences in the dopaminergic response to unpredictable reward in the human ventral striatum. European Journal of Neuroscience, 2011, 33, 1706-1715.	2.6	82
32	Reduced thalamic volumes in major depressive disorder. Psychiatry Research - Neuroimaging, 2013, 213, 179-185.	1.8	79
33	Neural correlates of rapid antidepressant response to ketamine in bipolar disorder. Bipolar Disorders, 2014, 16, 119-128.	1.9	74
34	No Change in Serotonin Type 1A Receptor Binding in Patients With Posttraumatic Stress Disorder. American Journal of Psychiatry, 2005, 162, 383-385.	7.2	70
35	What we learn about bipolar disorder from largeâ€scale neuroimaging: Findings and future directions from the <scp>ENIGMA</scp> Bipolar Disorder Working Group. Human Brain Mapping, 2022, 43, 56-82.	3.6	67
36	Sex differences in the neural correlates of autonomic arousal: A pilot PET study. International Journal of Psychophysiology, 2011, 80, 182-191.	1.0	63

#	Article	IF	Citations
37	The Functional DRD3 Ser9Gly Polymorphism (rs6280) Is Pleiotropic, Affecting Reward as Well as Movement. PLoS ONE, 2013, 8, e54108.	2.5	60
38	Ketamine modulates fronto-striatal circuitry in depressed and healthy individuals. Molecular Psychiatry, 2021, 26, 3292-3301.	7.9	57
39	DRD2/ANKK1 Taq1A polymorphism (rs1800497) has opposing effects on D2/3 receptor binding in healthy controls and patients with major depressive disorder. International Journal of Neuropsychopharmacology, 2013, 16, 2095-2101.	2.1	51
40	Ketamine normalizes brain activity during emotionally valenced attentional processing in depression. Neurolmage: Clinical, 2018, 20, 92-101.	2.7	51
41	Heart rate variability during motor and cognitive tasks in females with major depressive disorder. Psychiatry Research - Neuroimaging, 2011, 191, 1-8.	1.8	49
42	Ketamine metabolites, clinical response, and gamma power in a randomized, placebo-controlled, crossover trial for treatment-resistant major depression. Neuropsychopharmacology, 2020, 45, 1398-1404.	5.4	47
43	Neural Correlates of Suicidal Ideation and Its Reduction in Depression. International Journal of Neuropsychopharmacology, 2015, 18, pyu069-pyu069.	2.1	46
44	DEVELOPING BIOMARKERS IN MOOD DISORDERS RESEARCH THROUGH THE USE OF RAPID-ACTING ANTIDEPRESSANTS. Depression and Anxiety, 2014, 31, 297-307.	4.1	43
45	7T 1H-MRS in major depressive disorder: a Ketamine Treatment Study. Neuropsychopharmacology, 2018, 43, 1908-1914.	5.4	38
46	Evaluating global brain connectivity as an imaging marker for depression: influence of preprocessing strategies and placebo-controlled ketamine treatment. Neuropsychopharmacology, 2020, 45, 982-989.	5 <b>.</b> 4	37
47	Multimodal imaging reveals a complex pattern of dysfunction in corticolimbic pathways in major depressive disorder. Human Brain Mapping, 2019, 40, 3940-3950.	3.6	36
48	Preliminary differences in resting state MEG functional connectivity pre- and post-ketamine in major depressive disorder. Psychiatry Research - Neuroimaging, 2016, 254, 56-66.	1.8	35
49	Reliability of 7T <sup>1</sup> H-MRS measured human prefrontal cortex glutamate, glutamine, and glutathione signals using an adapted echo time optimized PRESS sequence: A between- and within-sessions investigation. Journal of Magnetic Resonance Imaging, 2016, 43, 88-98.	3.4	35
50	Synaptic potentiation and rapid antidepressant response to ketamine in treatment-resistant major depression: A replication study. Psychiatry Research - Neuroimaging, 2019, 283, 64-66.	1.8	34
51	Cerebrospinal Fluid Monocyte Chemoattractant Proteinâ€1 in Alcoholics: Support for a Neuroinflammatory Model of Chronic Alcoholism. Alcoholism: Clinical and Experimental Research, 2014, 38, 1301-1306.	2.4	33
52	Habenula volume in post-traumatic stress disorder measured with high-resolution MRI. Biology of Mood & Anxiety Disorders, 2011, 1, 7.	4.7	32
53	Amygdala response to explicit sad face stimuli at baseline predicts antidepressant treatment response to scopolamine in major depressive disorder. Psychiatry Research - Neuroimaging, 2016, 254, 67-73.	1.8	32
54	Reduced post-synaptic serotonin type 1A receptor binding in bipolar depression. European Neuropsychopharmacology, 2013, 23, 822-829.	0.7	30

#	Article	IF	CITATIONS
55	Association between subcortical volumes and verbal memory in unmedicated depressed patients and healthy controls. Neuropsychologia, 2012, 50, 2348-2355.	1.6	29
56	Baseline mood-state measures as predictors of antidepressant response to scopolamine. Psychiatry Research, 2012, 196, 62-67.	3.3	28
57	Baseline working memory activation deficits in dimensional anxious depression as detected by magnetoencephalography. Acta Neuropsychiatrica, 2015, 27, 143-152.	2.1	28
58	Shank3 as a potential biomarker of antidepressant response to ketamine and its neural correlates in bipolar depression. Journal of Affective Disorders, 2015, 172, 307-311.	4.1	27
59	Neurophysiological Changes Associated with Antidepressant Response to Ketamine Not Observed in a Negative Trial of Scopolamine in Major Depressive Disorder. International Journal of Neuropsychopharmacology, 2019, 22, 10-18.	2.1	27
60	Effects of Ketamine on Brain Activity During Emotional Processing: Differential Findings in Depressed Versus Healthy Control Participants. Biological Psychiatry: Cognitive Neuroscience and Neuroimaging, 2019, 4, 610-618.	1.5	26
61	Bcl-2 Polymorphism Influences Gray Matter Volume in the Ventral Striatum in Healthy Humans. Biological Psychiatry, 2009, 66, 804-807.	1.3	24
62	Mood stabilizer treatment increases serotonin type 1A receptor binding in bipolar depression. Journal of Psychopharmacology, 2013, 27, 894-902.	4.0	24
63	Research on the pathophysiology, treatment, and prevention of suicide: practical and ethical issues. BMC Psychiatry, 2019, 19, 332.	2.6	24
64	Neural mechanisms of antidepressant efficacy of the dopamine receptor agonist pramipexole in treatment of bipolar depression. International Journal of Neuropsychopharmacology, 2011, 14, 545-551.	2.1	23
65	The antidepressant efficacy of subanesthetic-dose ketamine does not correlate with baseline subcortical volumes in a replication sample with major depressive disorder. Journal of Psychopharmacology, 2017, 31, 1570-1577.	4.0	17
66	Serotonin transporter genotype and depressive phenotype determination by discriminant analysis of glucose metabolism under acute tryptophan depletion. NeuroImage, 2008, 43, 764-774.	4.2	16
67	Multilayer MEG functional connectivity as a potential marker for suicidal thoughts in major depressive disorder. NeuroImage: Clinical, 2020, 28, 102378.	2.7	15
68	The Effect of Ketamine on Electrophysiological Connectivity in Major Depressive Disorder. Frontiers in Psychiatry, 2020, 11, 519.	2.6	15
69	Pretreatment Differences in BOLD Response to Emotional Faces Correlate with Antidepressant Response to Scopolamine. International Journal of Neuropsychopharmacology, 2015, 18, pyv028-pyv028.	2.1	14
70	T1? imaging using magnetization-prepared projection encoding (MaPPE). Magnetic Resonance in Medicine, 2000, 43, 421-428.	3.0	13
71	Magnetoencephalographic Correlates of Suicidal Ideation in Major Depression. Biological Psychiatry: Cognitive Neuroscience and Neuroimaging, 2020, 5, 354-363.	1.5	12
72	On-scalp magnetocorticography with optically pumped magnetometers: Simulated performance in resolving simultaneous sources. Neurolmage Reports, 2022, 2, 100093.	1.0	12

#	Article	IF	CITATIONS
73	Biomarkers in mood disorders research: developing new and improved therapeutics. Revista De Psiquiatria Clinica, 2014, 41, 131-134.	0.6	11
74	Safety of research into severe and treatment-resistant mood disorders: analysis of outcome data from 12 years of clinical trials at the US National Institute of Mental Health. Lancet Psychiatry,the, 2016, 3, 436-442.	7.4	11
75	Deriving frequency-dependent spatial patterns in MEG-derived resting state sensorimotor network: A novel multiband ICA technique. Human Brain Mapping, 2017, 38, 779-791.	3.6	11
76	The Ethics of Clinical Trials Research in Severe Mood Disorders. Bioethics, 2017, 31, 443-453.	1.4	10
77	Active suicidal ideation during clinical antidepressant trials. Psychiatry Research, 2017, 257, 303-308.	3.3	9
78	Ketamine and Attentional Bias Toward Emotional Faces: Dynamic Causal Modeling of Magnetoencephalographic Connectivity in Treatment-Resistant Depression. Frontiers in Psychiatry, 2021, 12, 673159.	2.6	9
79	Altered interaction with environmental reinforcers in major depressive disorder: Relationship to anhedonia. Behaviour Research and Therapy, 2017, 97, 170-177.	3.1	8
80	Mapping anticipatory anhedonia: an fMRI study. Brain Imaging and Behavior, 2019, 13, 1624-1634.	2.1	8
81	Ketamine Alters Electrophysiological Responses to Emotional Faces in Major Depressive Disorder. Journal of Affective Disorders, 2021, 279, 239-249.	4.1	7
82	Effects of arterial cannulation stress on regional cerebral blood flow in major depressive disorder. Scientific Reports, 2012, 2, 308.	3.3	4
83	Catecholamine depletion in first-degree relatives of individuals with mood disorders: An [18F]fluorodeoxyglucose positron emission tomography study. Neurolmage: Clinical, 2013, 2, 341-355.	2.7	3
84	Magnetoencephalography biomarkers of suicide attempt history and antidepressant response to ketamine in treatment-resistant major depression. Journal of Affective Disorders, 2022, 312, 188-197.	4.1	3
85	Neuroimaging Promises and Caveats. , 2016, , .		0
86	Using Neuroimaging to Decipher the Mechanism of Action of Ketamine: A Pathway to Novel Therapeutics?. Biological Psychiatry: Cognitive Neuroscience and Neuroimaging, 2017, 2, 549-551.	1.5	0
87	Magnetoencephalography Studies in Mood Disorders. , 2021, , 192-205.		O